Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-009 in recurrent/metastatic head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy
2019-000569-19Phase 2Active
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Lenvatinib + pembrolizumab, Standard-of-care chemotherapy and Lenvatinib monotherapy (3 arms). Primary endpoint: Objective Response Rate. Started May 2020; status: active.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-000569-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000569-19.